Prothena to Report Second Quarter 2020 Financial Results on August 6

Rhea-AI Summary

Prothena Corporation plc (NASDAQ: PRTA) will announce its Q2 and H1 2020 financial results on August 6, after U.S. market close. The company specializes in neurodegenerative and rare peripheral amyloid diseases, with a pipeline of investigational therapeutics. Notably, Prothena collaborates with Roche on prasinezumab for Parkinson’s disease and partners with Bristol-Myers Squibb on therapies targeting Alzheimer’s and other diseases. Consistent with previous practices, there will be no conference call following the earnings release.

Positive

• Strong pipeline with multiple investigational therapeutics targeting neurodegenerative diseases.
• Partnership with Roche and Bristol-Myers Squibb indicates industry confidence in Prothena's programs.

Negative

• None.

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, announced today that it will report its second quarter and first six months of 2020 financial results on Thursday, August 6, after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 6.

About Prothena
Prothena Corporation plc is a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s partnered programs include prasinezumab (PRX002/RG7935), in collaboration with Roche for the potential treatment of Parkinson’s disease and other related synucleinopathies, and programs that target tau, TDP-43, and an undisclosed target in collaboration with Bristol-Myers Squibb for the potential treatment of Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) or other neurodegenerative diseases. Prothena’s proprietary programs include PRX004 for the potential treatment of ATTR amyloidosis, and programs that target Aβ (Amyloid beta) for the potential treatment of Alzheimer’s disease. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Media & Investor Contact:

Ellen Rose, Head of Communications
650-922-2405, ellen.rose@prothena.com

FAQ

When will Prothena report its Q2 2020 financial results?

Prothena will report its Q2 2020 financial results on August 6, 2020.

Will there be a conference call after the financial results announcement?

No, Prothena will not conduct a conference call following the financial results release on August 6.

What diseases does Prothena's pipeline target?

Prothena's pipeline targets neurodegenerative diseases and rare peripheral amyloid diseases.

What is the significance of Prothena's partnerships?

Prothena's collaborations with Roche and Bristol-Myers Squibb enhance its credibility and market potential in treating serious conditions.